Acadia Pharmaceuticals stock tumbles on mixed trial results
Acadia Pharmaceuticals (ACAD) shares dropped 6% after its Phase 2 RADIANT study for remlifanserin in Alzheimer’s disease psychosis missed the primary endpoint (p-value 0.0603) but achieved significance on a key secondary endpoint (p-value 0.0077). The company will continue Phase 3 studies, removing the 30 mg dosage. The drug showed a favorable safety profile. Detailed results will be presented at a 2026 conference.
How this was made
The 30-second read
Why it matters
The primary endpoint miss reduces near‑term revenue expectations and may delay regulatory milestones.
Market read
The trial outcome is a material catalyst for ACAD and influences sentiment in the broader neuro‑degenerative biotech space.
What to watch
Safety profile remains favorable and the company is continuing Phase 3 programs, which may mitigate the miss.
Background
Acadia Pharmaceuticals develops treatments for neuropsychiatric conditions; remlifanserin is its lead candidate for Alzheimer’s disease psychosis.
Ticker impact
Acadia Pharmaceuticals announced Phase 2 results that missed the primary endpoint, causing the stock to drop 6%.
Further downside of 3‑5% over the next few days as investors reassess valuation.
Phase 2 miss on a primary endpoint is material for a biotech; market already reacted with a 6% fall.
Market effects
Alzheimer's disease therapeutics sector may see heightened scrutiny on trial designs.
US biotech indices could see modest pullback.
Limited to investors focused on neuro‑degenerative drug pipelines.
Counterpoint
The secondary endpoint was statistically significant, which could support a future upside if Phase 3 confirms efficacy.
Key entities
- companyAcadia Pharmaceuticals Inc.
US‑listed biotech developing remlifanserin.
- clinical_trialRADIANT study
Phase 2 trial evaluating remlifanserin in Alzheimer’s disease psychosis.
